In a our previous blog post A Trio of Uses for Mometasone Furoate, we mentioned how the drug is used in Nasonex, to treat allergic rhinitis. On June 15, 2012, the U.S. District Court for the District of New Jersey ruled against Merck in their patent infringement suit against Apotex Inc. and Apotex Corp. Merck will likely appeal the decision sometime in the near future.
The patent at issue in this case is U.S. Patent No. 6,127,353 that covers mometasone furoate monohydrate, the active ingredient in NASONEX and which provides exclusivity for this form of mometasone until April 3, 2018.
Apotex is seeking U.S. Food and Drug Administration (FDA) approval to sell a generic version of NASONEX.